Clinical trial · Interventional
Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers
A Phase II Study of the Recombinant Human Monoclonal Anti-Vascular Endothelial Growth Factor Antibody (rhuMAB VEGF) Bevacizumab (NSC #704865, IND # 7,921) Administered in Times Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Refractory and Relapsed Acute Myelogenous Leukemias (AMLs)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Monoclonal antibodies such as bevacizumab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with chemotherapy may be an effective treatment for hematologic cancer. PURPOSE: Phase II trial to study the effectiveness of bevacizumab combined with cytarabine and mitoxantrone in treating patients who have hematologic cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bevacizumab | Biological | Bevacizumab | ALIAS |
| cytarabine | Drug | Cytarabine | ALIAS |
| mitoxantrone hydrochloride | Drug | Mitoxantrone | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically confirmed poor-risk hematologic malignancy
* Relapsed or refractory acute myelogenous leukemia (AML)
* Primary induction failure
* Myelodysplasia(MDS)-related AML
* Secondary AML
* Relapsed or refractory MDS
* Primary induction failure
* Refractory anemia with excess blasts (RAEB)
* RAEB in transformation
* Chronic myelomonocytic leukemia
* Chronic myelogenous leukemia in blast crisis
* Failure of prior primary induction therapy or relapse after achieving complete remission allowed only if no more than 3 courses of prior induction/reinduction therapy were received
* No hyperleukocytosis (50,000 or more leukemic blasts/mm3)
* No active CNS leukemia
PATIENT CHARACTERISTICS:
Age:
* 18 and over
Performance status:
* ECOG 0-2
Life expectancy:
* Not specified
Hematopoietic:
* See Disease Characteristics
* No disseminated intravascular coagulation
Hepatic:
* AST/ALT no greater than 2 times normal
* Alkaline phosphatase no greater than 2 times normal
* Bilirubin no greater than 1.5 times normal
Renal:
* Creatinine no greater than 1.5 times normal
Cardiovascular:
* LVEF at least 45% by MUGA or echocardiogram
* No myocardial infarction within the past 3 months
* No history of severe coronary artery disease
* No cardiomyopathy
* No New York Heart Association class III or IV heart disease (congestive heart failure)
Other:
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No active uncontrolled infection
* No history of cytarabine-related neurotoxicity
* No evidence of graft-versus-host disease
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* At least 1 week since prior hematopoietic growth factors including epoetin alfa, filgrastim (G-CSF), and sargramostim (GM-CSF)
* At least 1 week since prior interleukin-3 or interleukin-11
* At least 4 weeks since prior autologous stem cell transplantation
* At least 90 days since prior allogeneic stem cell transplantation
* No other concurrent immunotherapy
Chemotherapy:
* See Disease Characteristics
* At least 3 weeks since prior chemotherapy and recovered
* No prior cytarabine administered as a 72-hour continuous infusion followed by mitoxantrone IV over 30 minutes
* No other concurrent chemotherapy
Endocrine therapy:
* Not specified
Radiotherapy:
* No concurrent radiotherapy
Surgery:
* Not specified
Other:
* At least 2 weeks since prior immunosuppressive therapy
* No other concurrent investigational or commercially available antitumor therapyReferences
Publications (0)
Data not yet available